Amorfix Life Sciences' test detects scrapie prions in blood of scrapie-infected sheep



    TSX: AMF

    TORONTO, Oct. 25 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company
focused on diagnostics and treatments for brain-wasting diseases, today
announced the results from the testing of a blinded panel of blood samples
from scrapie infected sheep. Amorfix correctly identified 18 out of 20
individual sheep blood samples in a blinded panel provided by an independent
third-party laboratory, the Caine Veterinary Teaching Center, University of
Idaho.
    "These initial results demonstrate the ability of our diagnostic
technology to identify endogenous prions which is important for the
commercialization of our variant Creutzfeldt-Jacob Disease (vCJD) diagnostic
blood test," said Dr. George Adams, CEO of Amorfix Life Sciences. "These data
plus additional results that we will generate will be included in the
regulatory submission of a self-declared CE mark for the commercialization of
the EP-vCJD(TM) test. Moreover, while the EP-vCJD(TM) test is our lead
diagnostic candidate, these results present a new commercial opportunity for
the testing of all sheep and selective removal of infected animals."
    Dr. Marni Uger, Associate Director, Research and Development of Amorfix,
will be presenting these data at the European Commission workshop on vCJD
diagnostic assays in Brussels, Belgium tomorrow. Amorfix correctly scored 11
out of 12 positive samples and 7 out of 8 negative samples. It is unknown if
all sheep with scrapie have endogenous prions in their blood. At present there
is no effective blood diagnostic test that can identify scrapie prions in
sheep. Amorfix had previously reported the adaptation of its EP-vCJD(TM) assay
to detect sheep scrapie brain prions spiked into sheep plasma. The ability to
identify endogenous scrapie prions in the blood of sheep is a key milestone in
the development of Amorfix's EP-vCJD(TM) diagnostic test.
    Scrapie is a brain wasting disease found in sheep analogous to mad cow
disease in cattle and vCJD in humans.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.





For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 482-3813, Fax: (416) 482-3811,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 482-3814, Fax: (416) 482-3811,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890